Dublin-listed Open Orphan has signed an option to buy CHIMagents for a nominal sum. CHIMagents was recently established to assist in the design, manufacture and testing of challenge agents for use in clinical trials. Under the terms of the proposed deal Open Orphan will have three months to exercise its option to acquire CHIMagents. If the deal completes CHIMagents will be a standalone company within Open Orphan. CHIMagents will also support Hvivo's growing pipeline of challenge study clinical trials and help in accelerating the development of its Covid-19 challenge study clinical trials, according to a statement from Open Orphan.

Source: Irish Independent July 15, 2020 06:33 UTC